Skip to main content
  1. Right Decisions
  2. DGRefHelp - NHS Dumfries & Galloway
  3. Sexual health
  4. Back
  5. Infections - not STIs
  6. Urinary Tract Infection
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Urinary Tract Infection

Warning

WHATS NEW
Non-steroidal anti-inflammatory drugs can be considered in women >65 years with suspected uncomplicated lower UTI who describe their symptoms as mild

Symptoms occurring in both upper UTI (UUTI) and lower UTI (LUTI):

  • dysuria
  • urinary frequency
  • haematuria
  • lower abdominal tenderness
  • the presence of dysuria and frequency in women indicates a probability of UTI of over 90%.

Additional symptoms indicative of UUTI:

  • pyrexia
  • loin pain
  • systemic symptoms

Urinalysis

Diagnosis of UTI : primarily based on symptoms and signs,
However, urinalysis may contribute additional information to inform management. Dipstick tests are only indicated for women who have minimal signs and symptoms.
Where only one symptom or sign is present, a positive dipstick test (LE or nitrite) is associated with a high probability of bacteriuria (80%) and negative tests are associated with much lower probability (around 20%)

Mid Stream Sample of Urine (MSSU)

  • Send an MSSU before starting treatment, if there are symptoms or signs of upper UTI
  • No need to await the MSSU result before commencing treatment
  • In women consider possibility of pregnancy prior to treatment
  • Consider the possibility of STIs and PID and screen/treat appropriately
  • An MSSU should be sent from symptomatic pregnant women and from those in whom symptoms have persisted after empirical treatment
  • Narrow range antibiotics remain first line choice: broad spectrum drugs increase the risk of clostridium difficile, MRSA and resistant UTIs.

In uncomplicated lower UTI in non-pregnant women, treat with:-
nitrofurantoin 50mg orally four times daily for 3 days 
alternative trimethoprim 200mg orally twice daily for 3 days 
i.e. there is no need to send an MSSU at this point

In pregnant women 1st/2nd trimester, treat with:-
Nitrofurantoin 50mg orally four times daily for 7 days (theoretical risk neonatal haemolysis
at term)
(second-line: Cefalexin 500mg orally three times daily for 7 days)
(Trimethoprim 200mg twice daily for 7 days – off-label because folate metabolism)

In pregnant women 3rd trimester
Cefalexin 500mg orally three times daily for 7 days

If signs or symptoms of upper UTI are present, obtain an MSSU and treat
with:.
ciprofloxacin 500mg orally twice daily for 7 days (not if pregnant)
 co-amoxiclav 625mg orally three times daily for 7 days (for pregnancy or if allergy
cephalexin 500mg orally three times daily for 7 days)

lower UTI in men: trimethoprim 200mg orally twice daily for 7 days or nitrofurantoin
50mg orally four times daily for 7 days
upper UTI in men: ciprofloxacin 500mg orally twice daily for 7 days should be used for tissue
penetration – consider longer courses if signs of prostate involvement

  • Urinary tract infection is rare in young men. All men with proven UTI should be referred to their GP for referral for imaging of the renal tract (ultrasound or IVP). Men with recurrent UTI should be referred to a urologist.
  • Women with recurrent UTI may benefit from imaging of the renal tract and consideration of prophylactic antibiotics. This is best managed by urologists, following referral by the woman’s GP

 

  • Cranberry products – evidence shows prevention of symptomatic UTI in young adult women with recurrent UTI is almost as good as trimethoprim. Cranberry is available as tablets, capsules and juice. High strength is more convenient and efficacious. Less benefit in older men, women, and those requiring catheterisation. These products are not available on the NHS. 

N.B: Warfarin should not be taken with Cranberry products owing to pharmacokinetic interaction.

  • Oestrogen replacement locally has not been shown consistently to reduce the frequency of recurrent UTIs in women.
  • Consider NSAIDs as first-line treatment in women aged <65 years with suspected uncomplicated lower UTI who describe their symptoms as mild
  • Increasing fluid intake is thought to reduce UTI by dilution and flushing of bacteriuria. This reduces attachment to uroepithelial cells, reduces growth nutrients and/or improves clearance. While no evidence was identified for benefit, increasing fluid intake with water in women with urinary symptoms is a low-cost intervention without evidence of harm that may provide symptomatic relief.

 

Editorial Information

Last reviewed: 31/05/2024

Next review date: 31/05/2026

Author(s): West of Scotland Managed Clinical Network in Sexual Health Clinical Guidelines Group .

Version: 3.1

Approved By: West of Scotland Managed Clinical Network in Sexual Health